Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose

Diabetes

Volumn 51, Issue 4, 2002, Pages 951-957

  Greenbaum, Carla J ^a   Prigeon, Ronald L ^b   D'Alessio, David A ^c  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 0036224872     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.4.951     Document Type: Article

References (41)

1. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDtype 1 diabetic in ICA+ relatives: The ICARUS data set
2. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes
3. Relationship between first-phase insulin secretion and age, HLA, islet cell antibody status, and development of type I diabetes in 220 juvenile first-degree relatives of diabetic patients
4. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives
5. Pre-Type I diabetes: Linear loss of beta cell response to intravenous glucose
6. Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: Follow-up of the Seattle Family Study
7. Type 1 diabetes manifested solely by 2 hour OGTT criteria
8. Diabetic glucose tolerance may precede fasting hyperglycemia and abnormal HbA1c in type 1 subjects
9. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects
10. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
11. Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDtype 1 diabetic patients: 5-Yr follow-up of the Seattle Family Study
12. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons
13. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons
14. Immunoassay of insulin: Two antibody system: Plasms insulin levels of normal, subdiabetic and diabetic rats
15. Radioimmunoassays of gastrointestinal polypeptides
16. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)
17. Quantitative estimation of insulin sensitivity
18. Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDtype 1 diabetic) in relatives of patients with IDtype 1 diabetic
19. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
20. Banting lecture 1990: Beta-cells in type II diabetes mellitus
21. Abnormal glucose regulation of insulin secretion in models of reduced B-cell mass
22. Differential sensitivity to beta-cell secretagogues in early type I diabetes mellitus
23. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
24. The glucagon-like peptides
25. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
26. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans
27. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus
28. Impact of lack of suppression of glucagon on glucose tolerance in humans
29. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
30. Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus
31. Endocrine-metabolic function in remission-phase IDtype 1 diabetic during administration of cyclosporine
32. Pathophysiology of beta cell failure after prolonged remission of insulin-dependent diabetes mellitus (IDtype 1 diabetic)
33. C-peptide secretion during the remission phase of juvenile diabetes
34. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion
35. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
36. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance
37. Mott type 1 diabetic, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
38. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development
39. Impaired basal glucose effectiveness in NIDtype 1 diabetic: Contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol
40. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus
41. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations